Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Slimme beeldvorming om celtherapie te verbeteren
mei 2024 | Immuuntherapie, Leukemie, Lymfoom